Dermal PBPK Model For Psoriatic Skin: Clobetasol Propionate Case Study

Authors: Novakovic J, van Osdol W, Spires J, Le Merdy M, Tsakalozou E, Ghosh P, Lukacova V
Conference: AAPS
Keywords: AAPS2024, dermal pharmacokinetics (PK), gastroplus, PBPK, Transdermal Compartmental Absorption and Transit (TCAT™) model
Software: GastroPlus®
Division: PBPK

Purpose

Psoriasis is a chronic inflammatory disease often treated by drug products applied on the skin surface, and it is well accepted that disease-mediated physiological changes in the skin can significantly affect the permeation of active pharmaceutical ingredients (APIs) through the skin layers. Therefore, it is critical to understand how dermal pharmacokinetics (PK) can differ between healthy and psoriasis conditions. Dermal physiologically-based pharmacokinetic (PBPK) models can provide insight into drug partitioning in skin layers that are inaccessible or challenging to sample clinically. The purpose of this study is to demonstrate the utility of a dermal PBPK model in predicting Clobetasol Propionate (CP) dermal exposure in psoriasis patients. CP was selected as a case study based on the availability of dermal open flow microperfusion (dOFM) data in non-lesional and lesional skin in psoriatic patients [1].

By Jasmina Novakovic, William van Osdol, Jessica Spires, Maxime Le Merdy, Tsakalozou E, Ghosh P, Viera Lukacova

American Association of Pharmaceutical Scientists (AAPS) PharmSci 360, October 20-23, 2024, Salt Lake City, Utah